NCT05323955: An ongoing trial by Carey Anders, M.D.
This trial is ongoing. It must report results 1 year, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05323955 |
|---|---|
| Title | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 23, 2023 |
| Completion date | April 30, 2026 |
| Required reporting date | April 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |